An Overview of Recent Advances in Type 1 Diabetes Therapies

Jodie Yuanru Liu

doi:10.54097/64kaan94

Authors

Jodie Yuanru Liu

DOI:

https://doi.org/10.54097/64kaan94

Keywords:

Type 1 diabetes, insulin, immunotherapy, stem cell, beta-cell replacement.

Abstract

Type 1 diabetes(T1D) is an autoimmune disorder caused by the destruction of pancreatic beta-cell, with both genetic and environmental triggering factors. Many patients need to rely on injecting insulin to replace human insulin and survive, but it is hard to avoid other complications, as there are no complete methods to cure T1D yet. Many therapies other than insulin therapy are developing in progress with many unsolved problems. For example, challenges like safety problems, low production efficiency and feasibility are still overcoming. In this review, factors contributed to T1D and main types of T1D therapies with their recent advances are summarized, including advantages and current problems of therapies. This review can provide a general view of therapies for researchers interested in T1D. In the future, research is still needed, focusing on solving immune challenges in the long run and how to produce beta cell function normally by human body to completely cure the disease.

Downloads

Download data is not yet available.

References

[1] Subramanian S, Khan F, Hirsch I B. New advances in type 1 diabetes. BMJ (Clinical research ed.), 2024, 384: e075681.

[2] American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care, 2024, 47 (Suppl 1): S20–S42.

[3] El Nahas R, Al-Aghbar M A, Herrero L, et al. Applications of Genome-Editing Technologies for Type 1 Diabetes. International Journal of Molecular Sciences, 2023, 25 (1): 344.

[4] Gregory G A, Robinson T I G, Linklater S E, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. The Lancet Diabetes & Endocrinology, 2022, 10 (10): 741–760.

[5] Vantyghem M C, de Koning E J P, Pattou F, et al. Advances in β-cell replacement therapy for the treatment of type 1 diabetes. The Lancet, 2019, 394 (10205): 1274–1285.

[6] Giwa A M, Ahmed R, Omidian Z, et al. Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment. World Journal of Diabetes, 2020, 11 (1): 13–25.

[7] Wilson L M, Castle J R. Recent Advances in Insulin Therapy. Diabetes Technology & Therapeutics, 2020, 22 (12): 929–936.

[8] Chen S, Du K, Zou C. Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Research & Therapy, 2020, 11 (1): 275.

[9] Ni Q, Pham N B, Meng W S, et al. Advances in immunotherapy of type 1 diabetes. Advanced Drug Delivery Reviews, 2019, 139: 83–91.

[10] Brusko T M, Russ H A, Stabler C L. Strategies for durable β cell replacement in type 1 diabetes. Science, 2021, 373 (6554): 516–522.